VIR BIOTECHNOLOGY, I

VIR
Delayed Quote. Delayed  - 07/30 04:00:00 pm
35.65USD -2.03%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Other Biotechnology & Medical Research
Vir Biotechnology, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its product candidates include VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-2020. The Company is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218 is a subcutaneously administered HBV-targeting siRNA. VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody (mAb). VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb. VIR-1111 is a subcutaneously administered HIV T cell vaccine. VIR-2020 is a subcutaneously administered TB T cell vaccine.

Number of employees : 327 people.
Sales per Business
2020
Contract44.5058.3%
License22.7529.8%
Grant9.1211.9%
USD in Million
Sales per region
20192020
United States8.09100%76.37100%
USD in Million
Managers
Name Title
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Principal Accounting Officer
Vicki L. Sato Non-Executive Chairman
Michael E. Kamarck Chief Technology Officer
Phil Pang Chief Medical Officer
Herbert W. Virgin Chief Scientific Officer & Executive VP-Research
Steven Rice Chief Administrative Officer
Robert Taylor Nelsen Independent Director
Robert J. Perez Independent Director
Phillip A. Sharp Independent Director
Shareholders
Name Equities %
SB Investment Advisers (UK) Ltd. 22,616,666 17.4%
ARCH Venture Partners LLC 21,680,892 16.7%
Capital Research & Management Co. (International Investors) 11,822,763 9.09%
GlaxoSmithKline plc 6,626,027 5.10%
George Scangos 6,520,888 5.01%
Capital Research & Management Co. (World Investors) 5,862,315 4.51%
The Vanguard Group, Inc. 5,801,429 4.46%
Capital Research & Management Co. (Global Investors) 5,671,339 4.36%
Temasek Holdings Pte Ltd. (Investment Management) 5,518,644 4.24%
Baillie Gifford & Co. 3,817,148 2.94%
Company contact information
Vir Biotechnology, Inc.
499 Illinois Street
Suite 500
5th floor
San Francisco, CA 94158

Phone : +1.415.906.4324
Web : http://www.vir.bio
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
VIR BIOTECHNOLOGY, INC.33.12%4 636
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 907
CUREVAC N.V.-39.24%21 497
ALNYLAM PHARMACEUTICALS, INC.37.68%21 034
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.62.86%20 449
PHARMARON BEIJING CO., LTD.64.43%20 226
ICON PUBLIC LIMITED COMPANY24.77%19 385
BIO-TECHNE CORPORATION51.86%18 755
HANGZHOU TIGERMED CONSULTING CO., LTD-2.48%18 276
INCYTE CORPORATION-11.01%17 011
PPD, INC.34.78%16 203
NOVAVAX, INC.60.82%13 285
QIAGEN N.V.-0.11%12 050
PRA HEALTH SCIENCES, INC.0.00%10 965
INTELLIA THERAPEUTICS, INC.160.75%10 305
BACHEM HOLDING AG51.71%9 267
SYNEOS HEALTH, INC.31.62%9 265